Results 31 to 40 of about 1,053,987 (300)
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer. Efficacy in combination with hormonal therapy [PDF]
, 2012 Background: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no ...
Cognetti F. +10 more
core +3 more sources
Continued growth, continual progress, and continuous publications [PDF]
Metabolomics, 2015 Welcome to the twelfth volume of the new look Metabolomics. 2016 is an exciting time for metabolomics in terms of the continued growth and continual progress being made within all areas of this vibrant research field. Approximately 10,000 articles have been published per annum in the last 3 years, and this is likely to increase further.
openaire +2 more sources
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]
, 2016 Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L +9 more
core +1 more source
Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing [PDF]
, 2001 Checkpoints maintain order and fidelity in the cell cycle by blocking late-occurring events when earlier events are improperly executed. Here we describe evidence for the participation of Chk1 in an intra-S phase checkpoint in mammalian cells.
Feijoo, Carmen +6 more
core +2 more sources
Educação e Pesquisa, 2009 Neste artigo, discute-se a realização do direito à educação e a forma de organização do ensino na perspectiva de democratizá-la. Tem-se como pressuposto que os ciclos e a progressão continuada podem ser uma forma de organização do ensino que favorece a ...
Márcia Aparecida Jacomini
doaj +1 more source
Current perspective - Trastuzumab [PDF]
, 2009 This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast ...
Cameron, D.A., Hall, P.S.
core +1 more source
Chinese Journal of Lung Cancer, 2013 Background and objective The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in the treatment of the advanced non-small cell lung cancer (NSCLC), especially in the adenocarcinoma patients with activating EGFR
Lin LIN +6 more
doaj +1 more source
Cancer Reports, 2022 Background Cancer care during the Covid‐19 pandemic has been challenging especially in a developing country such as the Philippines. Oncologists were advised to prioritize chemotherapy based on the absolute benefit that the patient may receive, which ...
Jessa Gilda Pandy +3 more
doaj +1 more source
To the Gut Microbiome and Beyond: The Brain-First or Body-First Hypothesis in Parkinson’s Disease
Frontiers in Microbiology, 2022 There is continued debate regarding Parkinson’s disease etiology and whether it originates in the brain or begins in the gut. Recently, evidence has been provided for both, with Parkinson’s disease onset presenting as either a “body-first” or “brain ...
Nathan D. Nuzum +6 more
doaj +1 more source
, 2019 Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC).
Ahn, M-J +20 more
core +1 more source